Home > Insider Trading > Filing (0001104659-23-130499)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649904	Rhythm Pharmaceuticals Inc.	RYTM	Pharmaceutical Preparations (2834)	462159271

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1909855	Joseph Shulman	222 Berkeley Street, 12Th Floor Boston MA 02116	Chief Technical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-12-27	2,400	$21.38	6,141	No	4	M	Direct
Common Stock	Disposition	2023-12-27	5,015	$50.01	1,126	No	4	S	Direct
Common Stock	Acquisiton	2023-12-28	6,800	$21.38	7,926	No	4	M	Direct
Common Stock	Disposition	2023-12-28	7,926	$50.00	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2023-12-27	2,400	$0.00	2,400	$21.38
Common Stock	Stock Option (Right to Buy)	Disposition	2023-12-28	6,800	$0.00	6,800	$21.38

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
82,600		2030-07-26	No	4	M	Direct
75,800		2030-07-26	No	4	M	Direct

Footnotes

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $50.00 to $50.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $50.00 to $50.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.